GlaxoSmithkline Pharmaceuticals Limited reported revised unaudited standalone earnings results for the fourth quarter and audited standalone and consolidated earnings results for the year ended March 31, 2017. For the quarter, the standalone company reported total income of INR 7,985.7 million compared to INR 7,304.2 million a year ago. Profit before exceptional items and tax were INR 1,438.4 million against INR 1,466.9 million for the same period of last year. Profit before tax was INR 1,697.0 million against INR 1,625.3 million for the same period of last year. Profit for the period was INR 1,127.1 million or INR 13.3 per basic and diluted share not annualized against INR 1,060.4 million or INR 12.5 per basic and diluted share not annualized for the same period of last year. For the year, the standalone company reported total income of INR 30,662.7 million compared to INR 29,480.3 million a year ago. Profit before exceptional items and tax were INR 4,653.5 million against INR 5,736.3 million for the same period of last year. Profit before tax was INR 5,110.8 million against INR 5,759.4 million for the same period of last year. Profit for the period was INR 3,367.8 million or INR 39.8 per basic and diluted share not annualized against INR 3,745.3 million or INR 44.2 per basic and diluted share not annualized for the same period of last year. For the year, the consolidated company reported profit before exceptional items and tax of INR 4,654.6 million against INR 5,760.9 million for the same period of last year. Profit before tax was INR 5,111.9 million against INR 5,784.0 million for the same period of last year. Profit for the period was INR 3,368.2 million or INR 39.8 per basic and diluted share against INR 3,761.5 million or INR 44.4 per basic and diluted share not annualized for the same period of last year. Total income was INR 30,728.1 million against INR 29,606.8 million not annualized for the same period of last year.